These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 28267627)
21. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Deschuyteneer M; Elouahabi A; Plainchamp D; Plisnier M; Soete D; Corazza Y; Lockman L; Giannini S; Deschamps M Hum Vaccin; 2010 May; 6(5):407-19. PubMed ID: 20953154 [TBL] [Abstract][Full Text] [Related]
22. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196 [TBL] [Abstract][Full Text] [Related]
23. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods. Matić S; Masenga V; Poli A; Rinaldi R; Milne RG; Vecchiati M; Noris E Plant Biotechnol J; 2012 May; 10(4):410-21. PubMed ID: 22260326 [TBL] [Abstract][Full Text] [Related]
25. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110 [TBL] [Abstract][Full Text] [Related]
27. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Thönes N; Müller M Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733 [TBL] [Abstract][Full Text] [Related]
28. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
29. Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles. Gupta G; Glueck R; Rishi N Biologicals; 2017 Mar; 46():11-22. PubMed ID: 28012703 [TBL] [Abstract][Full Text] [Related]
30. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine. Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518 [TBL] [Abstract][Full Text] [Related]
31. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Pineo CB; Hitzeroth II; Rybicki EP Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054 [TBL] [Abstract][Full Text] [Related]
32. [Efficient expression of human papillomavirus type 16 (HPV16) capsid proteins L1 and L2 in E. coli]. Wang W; Zhou L; Sun Y Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):358-61. PubMed ID: 12759977 [TBL] [Abstract][Full Text] [Related]
33. Engineering of Recombinant Human Papillomavirus 16 L1 Protein for Incorporation with Kim J; Jeong KJ; Kim GJ; Choi JI J Microbiol Biotechnol; 2024 Sep; 34(9):1926-1932. PubMed ID: 39155395 [TBL] [Abstract][Full Text] [Related]
34. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660 [TBL] [Abstract][Full Text] [Related]
35. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177 [TBL] [Abstract][Full Text] [Related]
36. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. Li M; Cripe TP; Estes PA; Lyon MK; Rose RC; Garcea RL J Virol; 1997 Apr; 71(4):2988-95. PubMed ID: 9060658 [TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of soluble human papillomavirus L1 through coexpression of molecular chaperonin in Escherichia coli. Pan D; Zha X; Yu X; Wu Y Protein Expr Purif; 2016 Apr; 120():92-8. PubMed ID: 26732286 [TBL] [Abstract][Full Text] [Related]
38. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038 [TBL] [Abstract][Full Text] [Related]
39. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642 [TBL] [Abstract][Full Text] [Related]
40. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. Chen XS; Casini G; Harrison SC; Garcea RL J Mol Biol; 2001 Mar; 307(1):173-82. PubMed ID: 11243812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]